Quarterly report [Sections 13 or 15(d)]

STOCK-BASED COMPENSATION

v3.25.2
STOCK-BASED COMPENSATION
6 Months Ended
Jun. 30, 2025
Share-Based Payment Arrangement [Abstract]  
STOCK-BASED COMPENSATION

Note 13. STOCK-BASED COMPENSATION

 

The Company granted options and restricted stock awards under its 2014 Equity Incentive Plan (the “2014 Plan”). Under the 2014 Plan, the Company is authorized to grant options or restricted stock for up to 2,000,000 shares of Common Stock. On June 6, 2023, the Company received stockholder approval to increase the number of authorized shares from 1,142,857 to 2,000,000. Options or restricted stock awards may be granted to employees, the Company’s board of directors, and external consultants who provide services to the Company. Options and restricted stock awards granted under the 2014 Plan have vesting schedules with terms of one to three years and become fully exercisable based on specific terms imposed at the date of grant. The 2014 Plan expired according to the respective 10-year term of the 2014 Plan in March 2024. A new 2024 Incentive Compensation Plan (the “2024 Plan”) was approved at the Annual Meeting of Shareholders on June 4, 2024.

 

The Company has recorded stock-based compensation expense related to the issuance of restricted stock awards in the following line items in the accompanying condensed consolidated statements of operations:

 

    2025     2024     2025     2024  
    Three Months Ended
June 30,
    Six Months Ended
June 30,
 
    2025     2024     2025     2024  
                         
Research and development   $ (8,334 )   $ 35,345     $ 12,916     $ 57,227  
General and administrative     219,941       251,949       525,307       512,680  
Total stock-based compensation expense   $ 211,607     $ 287,294     $ 538,223     $ 569,907  

 

The following table summarizes stock option activity under the 2014 Plan and 2024 Plan:

 

SUMMARY OF OPTION ACTIVITY

    Number of
options
    Weighted-average
exercise price
    Weighted-average
remaining contractual
term (in years)
    Aggregate
intrinsic value
 
Outstanding at December 31, 2024     304,125     $ 6.95       4.45        
Granted                        
Exercised                        
Forfeited                        
Outstanding at June 30, 2025     304,125     $ 6.95       3.90        
                                 
Vested and exercisable at June 30, 2025     304,125     $ 6.95       3.90        

 

As of June 30, 2025, there was no unrecognized compensation cost related to non-vested stock options.

 

The following table summarizes restricted stock award activity under the 2014 Plan and 2024 Plan:

 

SUMMARY OF RESTRICTED STOCK AWARD

    Number of                 As of June 30, 2025  
    restricted
stock awards
(RSA)
    Weighted-
average
grant price
    FMV on
grant date
    Vested
number
of RSA
    Unvested
number
of RSA
 
Balance at December 31, 2024     1,326,861     $ 1.99     $ 2,636,259       1,215,592       171,671  
Granted     258,398       0.81       208,559       121,408       136,990  
Forfeited     (25,721 )     0.81       (20,834 )           (25,721 )
Balance at June 30, 2025     1,559,538     $ 1.81     $ 2,823,984       1,139,496       282,940  

 

During the three months ended June 30, 2025, the Company issued restricted stock awards (“RSAs”) for 5,000 shares of Common Stock to employees, non-employees, and the board of directors. The shares vest in equal monthly installments over terms of immediately and up to three years, subject to the employees and non-employees providing continuous service through the vesting date. During the six months ended June 30, 2025, 172,660 shares vested from RSAs granted prior to January 1, 2025, and 121,408 shares vested from RSAs granted during the six months ended June 30, 2025.